Esperion Therapeutics
ESPR • NASDAQ
Esperion Therapeutics is a drug manufacturers - specialty & generic company in the healthcare sector trading on NASDAQ, led by CEO Sheldon L. Koenig, with a market cap of $703.7M.
CEOSheldon L. Koenig
Market Cap$703.7M
Drug Manufacturers - Specialty & Generic
Healthcare
Employees240.0
Websiteesperion.com
Next Earnings
Upcoming earnings announcement for Esperion Therapeutics
Date
Tuesday, May 5, 2026 (in a month)
Timing
Before Market Open (6:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.03
Revenue Estimate
$90.8M
Earnings History
Past 12 earnings reports for Esperion Therapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 10, 2026 | Q4 2025 | $0.22Est: $0.26 | -15.4% | $168.4MEst: $163.9M | +2.8% |  10-K |
| Nov 6, 2025 | Q3 2025 | -$0.16Est: -$0.07 | -128.6% | $87.3MEst: $95.9M | -9.0% | 10-Q |
| Aug 5, 2025 | Q2 2025 | -$0.02Est: -$0.16 | +87.5% | $82.4MEst: $64.3M | +28.0% | 10-Q |
| May 6, 2025 | Q1 2025 | -$0.21Est: -$0.15 | -40.0% | $65.0MEst: $54.2M | +19.9% | 10-Q |
| Mar 4, 2025 | Q4 2024 | -$0.11Est: -$0.16 | +31.3% | $69.1MEst: $61.6M | +12.2% | 10-K |
| Nov 7, 2024 | Q3 2024 | -$0.15Est: -$0.18 | +16.7% | $51.6MEst: $51.3M | +0.6% | 10-Q |
| Aug 12, 2024 | Q2 2024 | -$0.05Est: -$0.15 | +66.7% | $73.8MEst: $50.6M | +45.9% | 10-Q |
| May 7, 2024 | Q1 2024 | $0.34Est: $0.05 | +580.0% | $137.7MEst: $84.5M | +63.0% | 10-Q |
| Feb 27, 2024 | Q4 2023 | -$0.50Est: -$0.48 | -4.2% | $32.3MEst: $28.7M | +12.4% | 10-K |
| Nov 7, 2023 | Q3 2023 | -$0.37Est: -$0.43 | +14.0% | $34.0MEst: $29.6M | +14.8% | — |
| Aug 1, 2023 | Q2 2023 | -$0.46Est: -$0.63 | +27.0% | $25.8MEst: $25.5M | +1.1% | 10-Q |
| May 9, 2023 | Q1 2023 | -$0.79Est: -$0.65 | -21.5% | $24.3MEst: $22.0M | +10.5% | — |